Showing 4351-4360 of 8827 results for "".
- The American Acne and Rosacea Society Offers #RosaceaRescues During Rosacea Awareness Monthhttps://practicaldermatology.com/news/the-american-acne-and-rosacea-society-offers-rosacearescues-during-rosacea-awareness-month/2461647/In recognition of National Rosacea Awareness Month in April, experts from the American Acne and Rosacea Society (AARS) are working to educate the public about the disease, its impact, and its treatment. Throughout the month, they are sharing #RosaceaRescues—science-backed, medically-based s
- Building a Better Sunscreen: Is Rosmarinic Acid the Key?https://practicaldermatology.com/news/building-a-better-sunscreen-is-rosmarinic-acid-the-key/2461646/Rosmarinic acid may enhance sunscreen efficacy without increasing concentration of conventional UV filters, a new study in Cosmetics suggests. When 0.1% Rosmarinic acid an active antioxidant was added
- It's Official: April Is the Coolest Month of the Yearhttps://practicaldermatology.com/news/its-official-april-is-the-coolest-month-of-the-year/2461642/April 2023 marks the first-ever CoolMonth, according to Allergan Aesthetics, an AbbVie company and the parent company of CoolSculpting Elite. Why April? A survey revealed 85% of people have a season in which they begin to think more about getting rid of stubborn body fat
- Lupus Research Alliance Collaborates with the FDA to Launch Public-Private Partnershiphttps://practicaldermatology.com/news/lupus-research-alliance-collaborates-with-the-fda-to-launch-public-private-partnership/2461641/The Lupus Research Alliance (LRA) announced the launched of Lupus Accelerating Breakthroughs Consortium (Lupus ABC), a public-private partnership. The goal of the partnership is to bring people with lupus together in collaboration with the F
- Phase 3 Data Evaluating Almirall’s Lebrikizumab in Moderate-to-Severe Atopic Dermatitis Publishedhttps://practicaldermatology.com/news/phase-3-data-evaluating-almiralls-lebrikizumab-in-moderate-to-severe-atopic-dermatitis-published/2461640/Almirall announced the publication of Week 16 and Week 52 results of ADvocate1 and ADvocate2 by the New England Journal of Medicine (NEJM) and the British Journal of Dermatology (BJD), respectively. ADvocate1 and ADvocate2 are two identical 52-week randomized, double-blind, plac
- Researchers Discover Anti-Aging Potential in an Invasive Weedhttps://practicaldermatology.com/news/researchers-discover-anti-aging-potential-in-an-invasive-weed/2461638/The fruit of the cocklebur plant, which grows worldwide and is often considered a noxious weed, has antioxidant and anti-inflammatory components that could make it useful as a skin protectant, according to new research
- Analysis Reveals How Incurable Skin Cancer Resists Treatmenthttps://practicaldermatology.com/news/research-autopsies-reveals-how-incurable-skin-cancer-resists-treatment/2461637/A new analysis published in the journal Cancer Discovery reveals how some skin cancers stop responding to treatment at the end of l
- FDA Approves Humira Biosimilar Hyrimozhttps://practicaldermatology.com/news/fda-approves-humira-biosimilar-hyrimoz/2461636/The FDA approved a citrate-free high-concentration formulation (HCF) of Hyrimoz (adalimumab-adaz; Sandoz) injection, a biosimilar to Humira (adalimumab). The adalimumab citrate-free HCF (100 mg/mL) is approved to treat seven indications covered by the reference medicine, Humira, in
- Study: Atopic Asthma/Eczema Linked to Heightened Risk of Osteoarthritishttps://practicaldermatology.com/news/study-atopic-asthmaeczema-linked-to-heightened-risk-of-osteoarthritis/2461635/People with atopic diseases like asthma or eczema may be at heightened risk of osteoarthritis, according to research published online in the Annals of the Rheumatic Diseases. Drugs used to dampen d
- Bristol Myers Squibb Receives European Commission Approval of Sotyktu for Plaque Psoriasishttps://practicaldermatology.com/news/bristol-myers-squibb-receives-european-commission-approval-of-sotyktu-for-plaque-psoriasis/2461634/The European Commission has approved Sotyktu (deucravacitinib; Bristol Myers Squibb), a first-in-class, selective tyrosine kinase 2 (TYK2) inhibitor, for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy. The approval was